KR20150053769A - 프리바이오틱 틸라코이드 조성물 - Google Patents

프리바이오틱 틸라코이드 조성물 Download PDF

Info

Publication number
KR20150053769A
KR20150053769A KR1020157008166A KR20157008166A KR20150053769A KR 20150053769 A KR20150053769 A KR 20150053769A KR 1020157008166 A KR1020157008166 A KR 1020157008166A KR 20157008166 A KR20157008166 A KR 20157008166A KR 20150053769 A KR20150053769 A KR 20150053769A
Authority
KR
South Korea
Prior art keywords
composition
thylakoid
bifidobacterium
lactobacillus
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157008166A
Other languages
English (en)
Korean (ko)
Inventor
퍼-아케 알버트슨
샬롯 얼랜슨 알버트슨
Original Assignee
틸라비스코 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 틸라비스코 아베 filed Critical 틸라비스코 아베
Publication of KR20150053769A publication Critical patent/KR20150053769A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/206—Bacterial extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020157008166A 2012-09-11 2013-09-10 프리바이오틱 틸라코이드 조성물 Withdrawn KR20150053769A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1251019 2012-09-11
SE1251019-4 2012-09-11
PCT/EP2013/068656 WO2014040962A1 (en) 2012-09-11 2013-09-10 Prebiotic thylakoid composition

Publications (1)

Publication Number Publication Date
KR20150053769A true KR20150053769A (ko) 2015-05-18

Family

ID=49209335

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157008166A Withdrawn KR20150053769A (ko) 2012-09-11 2013-09-10 프리바이오틱 틸라코이드 조성물

Country Status (13)

Country Link
US (1) US20150209396A1 (enExample)
EP (1) EP2895012B1 (enExample)
JP (1) JP6475162B2 (enExample)
KR (1) KR20150053769A (enExample)
CN (1) CN104780783A (enExample)
AU (1) AU2013314410B2 (enExample)
BR (1) BR112015005355A2 (enExample)
CA (1) CA2884281C (enExample)
DK (1) DK2895012T3 (enExample)
ES (1) ES2656619T3 (enExample)
NO (1) NO2895012T3 (enExample)
WO (1) WO2014040962A1 (enExample)
ZA (1) ZA201502431B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082466B1 (en) * 2013-12-18 2019-08-21 Thylabisco AB Use of thylakoids to reduce the urge for palatable food
DE112016002056T5 (de) * 2015-05-06 2018-02-08 Snipr Technologies Limited Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
JP6551934B2 (ja) * 2015-12-18 2019-07-31 森永乳業株式会社 ビフィドバクテリウム属細菌および／または乳酸菌の増殖促進および／または減少抑制剤
JP7244977B2 (ja) * 2016-03-11 2023-03-23 シオノギヘルスケア株式会社 腸内細菌叢調整用組成物
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1056358E (pt) 1998-02-24 2003-10-31 Arla Foods Amba Utilizacao de d-tagatose como componente alimentar prebiotico
US20030165557A1 (en) * 2000-09-19 2003-09-04 Sunstar, Inc. Food, medicine and method relating to Bifidobacterium proliferation promoting action, allergy preventive action and human cholesterol lowering action
JP2006025669A (ja) * 2004-07-14 2006-02-02 Kumamotoken Kajitsu Nogyo Kyodo Kumiai Rengokai 飲料の製造法
US7700139B2 (en) * 2004-12-30 2010-04-20 Commonwealth Scientific And Industrial Research Organization Method and means for improving bowel health
DK1893224T3 (en) 2005-06-10 2018-08-06 Thylabisco Ab APPLICATION OF PLANT CELL MEMBRANE TO TREAT OBESITAS
JP4819767B2 (ja) * 2006-12-12 2011-11-24 株式会社エス・エフ・シー イグサ青汁
US20080175899A1 (en) * 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
CN101278752A (zh) * 2008-01-29 2008-10-08 梁季鸿 即食卡尼汀天然果蔬饮料干粉系列配方及生产工艺
CA2730753A1 (en) 2008-07-14 2010-01-21 Thylabisco Ab Large-scale process for the preparation of thylakoids
WO2010146568A2 (en) * 2009-06-19 2010-12-23 Danisco A/S Bifidobacteria for treating diabetes and related conditions
CN103491947A (zh) * 2011-02-25 2014-01-01 西拉比索公司 一种用于延迟分子摄取的含有类囊体的组合物

Also Published As

Publication number Publication date
EP2895012B1 (en) 2017-10-18
AU2013314410B2 (en) 2017-02-23
US20150209396A1 (en) 2015-07-30
AU2013314410A1 (en) 2015-04-16
ES2656619T3 (es) 2018-02-27
NO2895012T3 (enExample) 2018-03-17
JP2015533484A (ja) 2015-11-26
BR112015005355A2 (pt) 2017-08-08
WO2014040962A1 (en) 2014-03-20
CA2884281A1 (en) 2014-03-20
CA2884281C (en) 2021-01-05
ZA201502431B (en) 2017-11-29
DK2895012T3 (en) 2018-01-22
CN104780783A (zh) 2015-07-15
JP6475162B2 (ja) 2019-02-27
EP2895012A1 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
Lim et al. Lactobacillus sakei OK67 ameliorates high-fat diet–induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression
Kerry et al. Benefaction of probiotics for human health: A review
Chiang et al. Beneficial effects of Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products
Boudry et al. Bovine milk oligosaccharides decrease gut permeability and improve inflammation and microbial dysbiosis in diet-induced obese mice
Nakata et al. Inhibitory effects of soybean oligosaccharides and water-soluble soybean fibre on formation of putrefactive compounds from soy protein by gut microbiota
Önal Darilmaz et al. The effects of inulin as a prebiotic supplement and the synbiotic interactions of probiotics to improve oxalate degrading activity
Montelius et al. Feeding spinach thylakoids to rats modulates the gut microbiota, decreases food intake and affects the insulin response
EP2457575B1 (en) New method for obtaining a Lactobacillus reuteri strain useful in medical and veterinary prophylaxis and treatment
Pahumunto et al. Anti-cancer properties of potential probiotics and their cell-free supernatants for the prevention of colorectal cancer: An in vitro study
Mikelsaar et al. Biodiversity of intestinal lactic acid bacteria in the healthy population
EP2457576A1 (en) New Lactobacillus reuteri strain useful in medical and veterinary prohylaxis and treatment
AU2013314410B2 (en) Prebiotic thylakoid composition
Cheng et al. Lactobacillus casei-fermented blueberry pomace augments sIgA production in high-fat diet mice by improving intestinal microbiota
Li et al. Apple polysaccharide could promote the growth of Bifidobacterium longum
Guo et al. Supplementation with yak (Bos grunniens) bone collagen hydrolysate altered the structure of gut microbiota and elevated short-chain fatty acid production in mice
KR20200143944A (ko) 글루텐 분해능을 가지는 락토바실러스 파라카제이 glu70 균주의 사균체를 유효성분으로 함유하는 글리아딘으로 야기된 염증성 장 질환의 예방, 개선 또는 치료용 조성물
Garcia-Gonzalez et al. Health-Promoting Role of Lactiplantibacillus plantarum Isolated from Fermented Foods. Microorganisms 2021, 9, 349
Miao et al. Oral administration of fermented milk supplemented with synbiotics can influence the physiological condition of Wistar rats in a dose-sensitive and sex-specific manner
Tijjani et al. Probiotics and their attributes in human health therapy
EP3793580A1 (en) Probiotic strain lactobacillus kefiri sgl 13 and use thereof for the prevention and treatment of intestinal inflammation and in the prevention of intestinal neoplasms
Shweta et al. In vitro studies on anti-inflammatory, antioxidant and antihyperglycemic activities of potential probiotic Pediococcus acidilactici NCDC 252
Kuda et al. Effect of food ingredients on susceptible gut indigenous bacteria
Tian The biotherapeutic potential of Lactobacillus reuteri DPC16 and bovine lactoferrin in controlling some pathogens, genotoxicity and inflammation in the gut: a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Engineering and Advanced Technology at Massey University, Auckland, New Zealand
Seshadri Understanding the role of probiotics as a possible treatment strategy for alcoholism induced liver dysfunction
Jangra et al. Living medicines for health and disease management

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000